Sandra Gardiner is recorded as CFO at Nektar Therapeutics (NKTR) since April 17, 2023. Nektar Therapeutics reported in an 8-K filed May 8, 2026 that Sandra Gardiner retired as interim Chief Financial Officer, effective May 15, 2026. Nektar Therapeutics reported in an 8-K filed April 17, 2023 that Sandra Gardiner was appointed interim Chief Financial Officer, effective April 17, 2023. The proxy statement of Nektar Therapeutics reports total compensation of $460,850 for Sandra Gardiner in fiscal 2024. Disclosed compensation is on record for 2 fiscal years. Sandra Gardiner has spoken on 8 earnings calls across 1 company, most recently for Nektar Therapeutics on May 7, 2026. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Linda Rubinstein (CFO), Jillian Thomsen (Chief Accounting Officer) and 1 other.
“On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.”
Nektar Therapeutics Form 8-K, filed May 8, 2026
· Read the filing
“Effective April 17, 2023, Sandra Gardiner, a partner in FLG Partners, LLC, a Silicon Valley chief financial officer services and board advisory firm (“FLG”), will be retained as the interim Chief Financial Officer and shall be the principal financial and accounting officer of the Company.”
Nektar Therapeutics Form 8-K, filed April 17, 2023
· Read the filing
Sandra Gardiner on recent calls
“On today's call, I'll review our quarterly financials for the first quarter of 2026 and provide updated cash guidance. We ended the first quarter of 2026 with $731.6 million in cash and investments with no debt on our balance sheet.”
“On today's call, I will review our quarterly and full year 2025 financials and share our preliminary financial guidance for 2026. We ended 2025 with $245.8 million in cash and investments and with no debt on our balance sheet.”
“On today's call, I'll briefly review our quarterly financials and share updates to our financial guidance for 2025. We ended the second quarter of 2025 with $175.9 million in cash and investments and with no debt on our balance sheet.”
“We ended the first quarter of 2025 with $220.7 million in cash and investments and with no debt on our balance sheet. We remain in a strong financial position and still expect our cash runway to extend into the fourth quarter of 2026 and to end 2025 with approximately $100 million in cash and investments.”
